Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities.

By G. Saito, J. Swanson, Kyung-Dall Lee. Advanced Drug Delivery Reviews, 2003

1,227 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. (2011, background): “The reduction-sensitive polymers, bioconjugates and vehicles have attracted a lot of attention for diverse biomedical applications including controlled drug delivery, gene delivery and diagnostic imaging [13,14].”
A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, background): “Lastly, intracellular glutathione (GSH) levels in tumor cells are 100–1000 fold higher than the extracellular levels [11].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, methodology): “For more information, please refer to Sawant and Torchilin (2010), Ganta et al. (2008), and Saito et al.(2003).”
Strategies in the design of nanoparticles for therapeutic applications (2010, background): “The reducing nature of the cytosol has been used extensively in protein–conjugate chemistry to trigger release of the payload on cellular internalization with cargos ranging from oligonucleotides to toxins and chemotherapeutic”